Format

Send to

Choose Destination
J Clin Oncol. 2018 Nov 16:JCO1800131. doi: 10.1200/JCO.18.00131. [Epub ahead of print]

SELECT: A Phase II Trial of Adjuvant Erlotinib in Patients With Resected Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer.

Author information

1
Nathan A. Pennell, Marc A. Shapiro, and Sudish Murthy, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; Joel W. Neal and Heather A. Wakelee, Stanford Cancer Institute and Stanford School of Medicine, Stanford, CA; Jamie E. Chaft, Valerie W. Rusch, and Mark G. Kris, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; Christopher G. Azzoli, Rebecca S. Heist, Alona Muzikansky, Michael Lanuti, and Lecia V. Sequist, Massachusetts General Hospital; Pasi A. Jänne, Dana-Farber Cancer Institute; Daniel B. Costa, Beth Israel Deaconess Medical Center, Boston, MA; Ramaswamy Govindan, Washington University School of Medicine, St. Louis, MO; and Tracey L. Evans, Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA.

Abstract

PURPOSE:

Given the pivotal role of epidermal growth factor receptor (EGFR) inhibitors in advanced EGFR-mutant non-small-cell lung cancer (NSCLC), we tested adjuvant erlotinib in patients with EGFR-mutant early-stage NSCLC.

MATERIALS AND METHODS:

In this open-label phase II trial, patients with resected stage IA to IIIA (7th edition of the American Joint Committee on Cancer staging system) EGFR-mutant NSCLC were treated with erlotinib 150 mg per day for 2 years after standard adjuvant chemotherapy with or without radiotherapy. The study was designed for 100 patients and powered to demonstrate a primary end point of 2-year disease-free survival (DFS) greater than 85%, improving on historic data of 76%.

RESULTS:

Patients (N = 100) were enrolled at seven sites from January 2008 to May 2012; 13% had stage IA disease, 32% had stage IB disease, 11% had stage IIA disease, 16% had stage IIB disease, and 28% had stage IIIA disease. Toxicities were typical of erlotinib; there were no grade 4 or 5 adverse events. Forty percent of patients required erlotinib dose reduction to 100 mg per day and 16% to 50 mg per day. The intended 2-year course was achieved in 69% of patients. The median follow-up was 5.2 years, and 2-year DFS was 88% (96% stage I, 78% stage II, 91% stage III). Median DFS and overall survival have not been reached; 5-year DFS was 56% (95% CI, 45% to 66%), 5-year overall survival was 86% (95% CI, 77% to 92%). Disease recurred in 40 patients, with only four recurrences during erlotinib treatment. The median time to recurrence was 25 months after stopping erlotinib. Of patients with recurrence who underwent rebiopsy (n = 24; 60%), only one had T790M mutation detected. The majority of patients with recurrence were retreated with erlotinib (n = 26; 65%) for a median duration of 13 months.

CONCLUSION:

Patients with EGFR-mutant NSCLC treated with adjuvant erlotinib had an improved 2-year DFS compared with historic genotype-matched controls. Recurrences were rare for patients receiving adjuvant erlotinib, and patients rechallenged with erlotinib after recurrence experienced durable benefit.

PMID:
30444685
DOI:
10.1200/JCO.18.00131

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center